Investors Getting Picky When It Comes To Buying Integra Lifesciences Holdings Corp (IART)

Integra Lifesciences Holdings Corp (NASDAQ:IART) does about 1.01M shares in volume on a normal day but saw 1420261 shares change hands in Friday’s trading. The company now has a market cap of 2.05B USD. Its current market price is $25.99, marking an increase of 2.73% compared to the previous close of $25.30. The 52 week high reached by this stock is $50.78 whilst the lowest price level in 52 weeks is $22.36.

Integra Lifesciences Holdings Corp (IART) has a 20-day trading average at $28.51 and the current price is -48.82% off the 52-week high compared with 16.23% distance from its 52-week low. The 50-day simple moving average of the closing price is $32.25 and its 200-day simple moving average is $38.74. If we look at the stock’s price movements over the week, volatility stands at 11.07%, which decreases to 5.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 34.50 to suggest the stock is neutral.

The consensus objective for the share price is $33.80, suggesting that the stock has a potential upside of 23.11% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 07, 2024 when Wells Fargo downgraded the stock to “Equal Weight” and issued a price target of between $45 and $25. Citigroup upgraded its price target at $38.

Integra Lifesciences Holdings Corp (IART) stock is down -10.04% over the week and -21.60% over the past month. Its price is -40.32% year-to-date and -48.06% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of 0.71 above consensus estimates by 0.14. The company’s next earnings report forecasts estimating quarterly EPS at 0.66 and 3.07 for whole year. Expected sales for next quarter are $430.29M, which analysts say will come at $1.66B for the current fiscal year and next year at $1.77B. In addition, estimates put the company’s current quarterly revenue at an average of $411.19M.

To reach the target analysts have set, the stock logically needs to grow 23.11 percent from here.

The company has a return on investment of 1.12% and return on equity of 2.46%. The price to earnings ratio (P/E ratio) amounts to 51.27 while the forward price to earnings ratio is 7.79. The beta has a value of 1.14. Price to book ratio is 1.28 and price to sales ratio is 1.34.